Interpace Biosciences, Inc. financial data

Symbol
IDXG on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ
Fiscal year end
December 31
Former names
Interpace Diagnostics Group, Inc. (to 11/1/2019), PDI INC (to 12/22/2015), PROFESSIONAL DETAILING INC (to 11/13/2002)
Latest financial report
10-Q - Q1 2025 - May 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 103 % +3.83%
Quick Ratio 11.3 % +7.95%
Debt-to-equity -65.2 % -47.2%
Return On Equity -28.9 % -654%
Return On Assets 54.3 % +251%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.42M shares +1.07%
Common Stock, Shares, Outstanding 4.42M shares +1.07%
Entity Public Float 4M USD +5.65%
Common Stock, Value, Issued 407K USD +0.25%
Weighted Average Number of Shares Outstanding, Basic 4.42M shares +1.14%
Weighted Average Number of Shares Outstanding, Diluted 27.7M shares +532%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 48.3M USD +19%
Cost of Revenue 17.3M USD +12.7%
Research and Development Expense 716K USD +14.7%
Selling and Marketing Expense 11.6M USD +8.74%
General and Administrative Expense 9.8M USD +7.57%
Operating Income (Loss) 8.82M USD +108%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 7.91M USD +216%
Income Tax Expense (Benefit) 18K USD +5.88%
Net Income (Loss) Attributable to Parent 7.64M USD +256%
Earnings Per Share, Basic 1.63 USD/shares +233%
Earnings Per Share, Diluted 0.3 USD/shares -38.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.2M USD -57.5%
Accounts Receivable, after Allowance for Credit Loss, Current 8.77M USD +75.2%
Inventory, Net 1.21M USD +4.77%
Other Assets, Current 1.69M USD +5.76%
Assets, Current 11.7M USD +23.8%
Property, Plant and Equipment, Net 1.28M USD +38.1%
Operating Lease, Right-of-Use Asset 1.52M USD -13.6%
Other Assets, Noncurrent 45K USD 0%
Assets 14.5M USD +19.4%
Accounts Payable, Current 1.73M USD +27.1%
Employee-related Liabilities, Current 1.82M USD +108%
Liabilities, Current 8.68M USD -31.1%
Long-term Debt and Lease Obligation 1.75M USD -41.1%
Operating Lease, Liability, Noncurrent 1.08M USD -20.5%
Other Liabilities, Noncurrent 5.32M USD +4.85%
Liabilities 15.1M USD -26%
Retained Earnings (Accumulated Deficit) -234M USD +3.17%
Stockholders' Equity Attributable to Parent -582K USD +98.9%
Liabilities and Equity 14.5M USD +19.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.24M USD
Net Cash Provided by (Used in) Financing Activities -1.5M USD -150%
Net Cash Provided by (Used in) Investing Activities -28K USD +56.9%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.56M shares +1.65%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -265K USD +61.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.2M USD -57.5%
Deferred Tax Assets, Valuation Allowance 35.1M USD -4.99%
Operating Lease, Liability 1.47M USD -15%
Payments to Acquire Property, Plant, and Equipment 28K USD -56.9%
Lessee, Operating Lease, Liability, to be Paid 1.79M USD -19.5%
Property, Plant and Equipment, Gross 4.21M USD +26.2%
Operating Lease, Liability, Current 394K USD +5.07%
Lessee, Operating Lease, Liability, to be Paid, Year Two 550K USD +10%
Lessee, Operating Lease, Liability, to be Paid, Year One 550K USD +22.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 313K USD -35.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 275K USD -50%
Deferred Tax Assets, Operating Loss Carryforwards 24.1M USD -3.43%
Preferred Stock, Shares Authorized 5M shares
Unrecognized Tax Benefits 877K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 275K USD
Amortization of Intangible Assets 900K USD -30.8%
Depreciation, Depletion and Amortization 95K USD +82.7%
Deferred Tax Assets, Net of Valuation Allowance 168K USD +700%
Share-based Payment Arrangement, Expense 227K USD -56.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares